Format

Send to

Choose Destination
See comment in PubMed Commons below
Parkinsonism Relat Disord. 2008 Aug;14(6):505-8. doi: 10.1016/j.parkreldis.2007.11.007. Epub 2008 Mar 5.

Blood-brain barrier P-glycoprotein function is not impaired in early Parkinson's disease.

Author information

1
Department of Neurology, University Medical Centre Groningen, University of Groningen, Groningen, Netherlands. a.l.bartels@neuro.umcg.nl

Abstract

The cause of Parkinson's disease (PD) is unknown. Genetic susceptibility and exposure to environmental toxins contribute to specific neuronal loss in PD. Decreased blood-brain barrier (BBB) P-glycoprotein (P-gp) efflux function has been proposed as a possible causative link between toxin exposure and PD neurodegeneration. In the present study BBB P-gp function was investigated in vivo in 10 early stage PD patients and 8 healthy control subjects using (R)-[(11)C]-verapamil and PET. Cerebral volume of distribution (V(d)) of verapamil was used as measure of P-gp function. Both region of interest (ROI) analysis and voxel analysis using statistical parametric mapping (SPM) were performed to assess regional brain P-gp function. In addition, MDR1 genetic polymorphism was assessed. In the present study, a larger variation in V(d) of (R)-[(11)C]-verapamil was seen in the PD group as compared to the control group. However, decreased BBB P-gp function in early stage PD patients could not be confirmed.

[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Support Center